International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)
Year: 2008
Type: conference-abstract
Source: Blood
Institutions: Newcastle University, Inserm, Centre Hospitalier Universitaire de Poitiers, Hammersmith Hospital, Imperial College London, Medizinische Fakultät Mannheim, South Australia Pathology, Fred Hutch Cancer Center, Novartis (United States), Novartis (Switzerland), Oregon Health & Science University, University of Chicago
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: chronic myeloid leukemia, chronic phase, imatinib, interferon, IRIS trial, event-free survival, progression-free survival, complete cytogenetic response, major molecular response, accelerated phase, blast crisis, long-term outcomes, drug safety, treatment discontinuation, molecular relapse, overall survival, major cytogenetic response
Open Access status: closed
OpenAlex ID: W2467057658
